A multi-centre, open-label, uncontrolled, phase II study to investigate efficacy and safety of ONO-4538 in malignant pleural mesothelioma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Mar 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- Sponsors Ono Pharmaceutical
- 24 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 25 Nov 2016 Status changed from not yet recruiting to recruiting.
- 10 Jun 2016 New trial record